利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.021 秒)

    Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor
    3.
    发明授权
    Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor 有权
    含有HIF-1α和HIF-2α表达抑制剂的药物

    公开(公告)号：US08268794B2

    公开(公告)日：2012-09-18

    申请号：US12672473

    申请日：2008-08-05

    申请人： Takeshi Nakajima ,  Emi Nakajima ,  Mitsuyoshi Azuma

    发明人： Takeshi Nakajima ,  Emi Nakajima ,  Mitsuyoshi Azuma

    IPC分类号： A61K48/00 ,  C07H21/02 ,  C07H21/04

    CPC分类号： A61K45/06 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/14

    摘要： Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1α expression and a substance specifically inhibiting HIF-2α expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1α and HIF-2α, or expression vectors thereof.

    摘要翻译： 本发明提供在治疗与血管生成相关的视网膜疾病如老年性黄斑变性，糖尿病性视网膜病变等中具有高治疗效果的药物。 含有特异性抑制HIF-1α表达的物质的视网膜疾病治疗剂和特异性抑制HIF-2α表达的物质。 作为本发明的治疗剂中的活性成分的上述抑制物质是能够诱导HIF-1α和HIF-2α的RNAi，反义核酸或核酶的核酸或其表达载体。

    PARTIAL PEPTIDE OF LACRITIN
    4.
    发明申请
    PARTIAL PEPTIDE OF LACRITIN 有权
    LACRITIN的部分肽

    公开(公告)号：US20110008891A1

    公开(公告)日：2011-01-13

    申请号：US12922084

    申请日：2009-03-19

    申请人： Takeshi Nakajima ,  Mitsuyoshi Azuma

    发明人： Takeshi Nakajima ,  Mitsuyoshi Azuma

    IPC分类号： C12N5/071 ,  C07K14/47

    CPC分类号： C07K14/475 ,  A61K9/0048 ,  A61K38/00

    摘要： The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells.

    摘要翻译： 本发明提供了包含SEQ ID NO：1的氨基酸序列的多肽，其是lacritin的特定部分序列，并且具有不超过70个残基的氨基酸长度。 本发明的多肽可以促进细胞和细胞外基质之间的粘附，并且可以促进泪腺腺泡细胞的泪液分泌。

    CELL CAPABLE OF EXPRESSING LACRITIN AT HIGH LEVEL
    5.
    发明申请
    CELL CAPABLE OF EXPRESSING LACRITIN AT HIGH LEVEL 审中-公开
    细胞能够在高水平上表达LACRITIN

    公开(公告)号：US20100183572A1

    公开(公告)日：2010-07-22

    申请号：US12449833

    申请日：2008-02-27

    申请人： Takeshi Nakajima ,  Mitsuyoshi Azuma

    发明人： Takeshi Nakajima ,  Mitsuyoshi Azuma

    IPC分类号： A61K35/44 ,  C12N15/85 ,  C12N5/10 ,  C12N15/00 ,  C12P21/02 ,  A61P27/02

    CPC分类号： C12N15/67 ,  A61K35/30 ,  A61K38/22 ,  A61K48/00 ,  C07K14/4702 ,  C12N5/0621 ,  C12N15/85 ,  C12N2510/02 ,  C12N2830/42 ,  C12N2830/85 ,  A61K2300/00

    摘要： The present invention relates to a means that allows supplying lacritin stably and in large amounts, and provides a vector containing polynucleotide that encodes lacritin, wherein said nucleotide is operatively linked to a cytomegalovirus immediate early enhancer/promoter and an SV40 late polyA signal, a lacritin-expressing cell prepared by introducing the vector into a cell, a method of producing recombinant lacritin, including the step of culturing the lacritin-expressing cell in a medium, and the step of isolating lacritin in the culture supernatant, and an agent for treating ocular disease containing the lacritin-expressing cell.

    摘要翻译： 本发明涉及一种能够稳定和大量供应lacritin的方法，并且提供了编码lacritin的含有多核苷酸的载体，其中所述核苷酸可操作地连接到巨细胞病毒立即早期增强子/启动子和SV40晚期polyA信号，lacritin 通过将载体导入细胞而制备的表达细胞，制备重组lacritin的方法，包括在培养基中培养表达lacritin的细胞的步骤，以及分离培养上清液中的lacritin的步骤和用于治疗眼睛的药剂 含有lacritin表达细胞的疾病。

    Partial peptide of lacritin
    6.
    发明授权
    Partial peptide of lacritin 有权
    泪蛋白的部分肽

    公开(公告)号：US08383130B2

    公开(公告)日：2013-02-26

    申请号：US12922084

    申请日：2009-03-19

    申请人： Takeshi Nakajima ,  Mitsuyoshi Azuma

    发明人： Takeshi Nakajima ,  Mitsuyoshi Azuma

    IPC分类号： A61K38/18 ,  C07K14/435 ,  C07K14/475

    CPC分类号： C07K14/475 ,  A61K9/0048 ,  A61K38/00

    摘要： The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells.

    摘要翻译： 本发明提供了包含SEQ ID NO：1的氨基酸序列的多肽，其是lacritin的特定部分序列，并且具有不超过70个残基的氨基酸长度。 本发明的多肽可以促进细胞和细胞外基质之间的粘附，并且可以促进泪腺腺泡细胞的泪液分泌。

    PHARMACEUTICAL CONTAINING HIF-1 ALPHA AND HIF-2 ALPHA EXPRESSION INHIBITOR
    7.
    发明申请
    PHARMACEUTICAL CONTAINING HIF-1 ALPHA AND HIF-2 ALPHA EXPRESSION INHIBITOR 有权
    包含HIF-1 ALPHA和HIF-2 ALPHA表达抑制剂的药物

    公开(公告)号：US20110213008A1

    公开(公告)日：2011-09-01

    申请号：US12672473

    申请日：2008-08-05

    申请人： Takeshi Nakajima ,  Emi Nakajima ,  Mitsuyoshi Azuma

    发明人： Takeshi Nakajima ,  Emi Nakajima ,  Mitsuyoshi Azuma

    IPC分类号： A61K31/713 ,  A61P27/02

    CPC分类号： A61K45/06 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/14

    摘要： Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1α expression and a substance specifically inhibiting HIF-2α expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1α and HIF-2α, or expression vectors thereof.

    摘要翻译： 本发明提供在治疗与血管生成相关的视网膜疾病如老年性黄斑变性，糖尿病性视网膜病变等中具有高治疗效果的药物。 含有特异性抑制HIF-1α表达的物质的视网膜疾病治疗剂和特异性抑制HIF-2α表达的物质。 作为本发明的治疗剂中的活性成分的上述抑制物质是能够诱导HIF-1α和HIF-2α的RNAi，反义核酸或核酶的核酸或其表达载体。

    Angiogenesis inhibitor
    8.
    发明授权
    Angiogenesis inhibitor 失效
    血管生成抑制剂

    公开(公告)号：US06214800B1

    公开(公告)日：2001-04-10

    申请号：US09282501

    申请日：1999-04-09

    申请人： Chiho Fukiage ,  Mitsuyoshi Azuma ,  Jun Inoue ,  Masayuki Nakamura ,  Yuka Yoshida

    发明人： Chiho Fukiage ,  Mitsuyoshi Azuma ,  Jun Inoue ,  Masayuki Nakamura ,  Yuka Yoshida

    IPC分类号： A61K3800

    CPC分类号： A61K38/55 ,  C07C311/19 ,  C07D303/48

    摘要： An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I) and compounds of the formula (VI) can be used. The angiogenesis inhibitor of the present invention suppresses new formation of blood vessels in the living tissues, so that it can be used as a superior therapeutic or prophylactic agent of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; and angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, senile discoid macular degeneration and the like, as well as for prevention of metastasis of tumors.

    摘要翻译： 一种包含半胱氨酸蛋白酶抑制化合物的血管生成抑制剂。 作为优选的半胱氨酸蛋白酶抑制化合物，可以使用环氧琥珀酸化合物，肽卤代酰肼化合物，钙蛋白酶抑制化合物，式（I）的化合物和式（VI）的化合物。 本发明的血管发生抑制剂抑制活组织中血管的新形成，可以用作与伤口愈合，炎症，肿瘤生长等有关的血管生成的优异治疗或预防剂。 和血管生成，如糖尿病视网膜病变，早产儿视网膜病变，视网膜静脉闭塞，老年性盘状黄斑变性等，以及用于预防肿瘤转移。

    Corneal Neuritogenesis Promoter Containing Pacap and Its Derivative
    9.
    发明申请
    Corneal Neuritogenesis Promoter Containing Pacap and Its Derivative 审中-公开
    包含Pacap及其衍生物的角膜神经发生启动子

    公开(公告)号：US20110212899A1

    公开(公告)日：2011-09-01

    申请号：US11578796

    申请日：2005-04-21

    申请人： Yoshiko Takayama ,  Yoshikuni Nakamura ,  Yutaka Inoue ,  Chiho Yabuta ,  Mitsuyoshi Azuma ,  Satomi Onoue

    发明人： Yoshiko Takayama ,  Yoshikuni Nakamura ,  Yutaka Inoue ,  Chiho Yabuta ,  Mitsuyoshi Azuma ,  Satomi Onoue

    IPC分类号： A61K38/17 ,  A61P27/02

    CPC分类号： A61K38/2278

    摘要： It is intended to provide an agent for promoting corneal neuritogenesis containing PACAP, a PACAP derivative or a pharmaceutically acceptable salt thereof, in particular, an agent for promoting corneal neuritogenesis aiming at improving corneal sensitivity, treating dry eye and treating corneal epithelial injury due to an effect of promoting corneal neuritogenesis. This agent for promoting corneal neuritogenesis is useful as a drug for ameliorating reduction in corneal sensitivity following corneal surgeries such as laser keratonomy (LASIK) and corneal grafting or cataract surgery, reduction in corneal sensitivity accompanying corneal neurodegeneration and dry eye symptom and corneal epithelial injury accompanying such reduction in corneal sensitivity. Moreover, it is useful as a drug for ameliorating dry eye symptom, reduction in corneal sensitivity and corneal epithelial injury in patients with dry eye, and a drug for ameliorating corneal epithelial injury and dry eye symptom and reduction in corneal sensitivity accompanying therewith.

    摘要翻译： 旨在提供用于促进包含PACAP，PACAP衍生物或其药学上可接受的盐的角膜神经发生的药剂，特别是用于促进角膜神经突发生的药物，其目的在于改善角膜敏感性，治疗干眼症并治疗角膜上皮损伤 促进角膜神经发生的作用。 用于促进角膜神经发生的药物可用作改善角膜手术如角膜手术（LASIK）和角膜移植术或白内障手​​术后角膜敏感性降低的药物，伴随角膜神经变性和干眼症状以及角膜上皮损伤伴随的角膜敏感性降低 角膜敏感度降低。 此外，它可用作改善干眼症状，减少干眼症患者的角膜敏感性和角膜上皮损伤的药物，以及用于改善角膜上皮损伤和干眼症状以及与之伴随的角膜敏感性降低的药物。